

Global Granulomatosis With Polyangiitis Drug Market Research Report 2025(Status and Outlook)

<https://marketpublishers.com/r/GE0030AA4F08EN.html>

Date: October 2025

Pages: 147

Price: US\$ 3,200.00 (Single User License)

ID: GE0030AA4F08EN

Abstracts

Report Overview

The global Granulomatosis With Polyangiitis Drug market size was estimated at USD 635.42 million in 2024 and is projected to grow at a compound annual growth rate (CAGR) of 6.85% during the forecast period.

This report offers a comprehensive and in-depth analysis of the global Granulomatosis With Polyangiitis Drug market, covering all critical facets from a broad macroeconomic overview to detailed micro-level insights. It examines market size, competitive landscape, emerging development trends, niche segments, key drivers and challenges, as well as conducts SWOT and value chain analyses.

The insights provided enable readers to understand the competitive dynamics within the industry and formulate effective strategies to enhance profitability and market positioning. Additionally, the report presents a clear framework for evaluating the current status and future outlook of business organizations operating in this sector.

A significant focus of this report lies in the competitive landscape of the global Granulomatosis With Polyangiitis Drug market. It offers detailed profiles of major players, including their market shares, performance metrics, product portfolios, and operational status. This enables stakeholders to identify leading competitors and gain a nuanced understanding of market rivalry and structure.

In summary, this report serves as an essential resource for industry participants, investors, researchers, consultants, and business strategists, as well as anyone planning to enter or expand their presence in the Granulomatosis With Polyangiitis Drug

market

Global Granulomatosis With Polyangiitis Drug Market: Market Segmentation Analysis

This research report provides a detailed segmentation of the market by region (country), key manufacturers, product type, and application. Market segmentation divides the overall market into distinct subsets based on factors such as product categories, end-user industries, geographic locations, and other relevant criteria.

A clear understanding of these market segments enables decision-makers to tailor their product development, sales, and marketing strategies more effectively to meet the unique needs of each segment. Leveraging market segmentation insights can significantly enhance targeted approaches, optimize resource allocation, and accelerate product innovation cycles by aligning offerings with the specific demands of diverse customer groups.

Key Company

Bionovis SA
Bristol-Myers Squibb Company
ChemoCentryx Inc
Coherus BioSciences Inc
Genor BioPharma Co Ltd
GlaxoSmithKline Plc
Iltoo Pharma
Panacea Biotec Ltd
Sandoz International GmbH
The International Biotechnology Center (IBC) Generium

Market Segmentation (by Type)

Benralizumab
Avacopan
Rituximab Biosimilar
Others

Market Segmentation (by Application)

Hospital
Clinic
Others

Geographic Segmentation

North America (USA, Canada, Mexico)

Europe (Germany, UK, France, Russia, Italy, Rest of Europe)

Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)

South America (Brazil, Argentina, Columbia, Rest of South America)

The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)

Key Benefits of This Market Research:

Industry drivers, restraints, and opportunities covered in the study

Neutral perspective on the market performance

Recent industry trends and developments

Competitive landscape & strategies of key players

Potential & niche segments and regions exhibiting promising growth covered

Historical, current, and projected market size, in terms of value

In-depth analysis of the Granulomatosis With Polyangiitis Drug Market

Overview of the regional outlook of the Granulomatosis With Polyangiitis Drug Market.

Customization of the Report

In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.

Chapter Outline

Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.

Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Granulomatosis With Polyangiitis Drug Market and its likely evolution in the short to mid-term, and long term.

Chapter 3 makes a detailed analysis of the market's competitive landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.

Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.

Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 9 shares the main producing countries of Granulomatosis With Polyangiitis

Drug, their output value, profit level, regional supply, production capacity layout, etc. from the supply side.

Chapter 10 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.

Chapter 11 provides a quantitative analysis of the market size and development potential of each region in the next five years.

Chapter 12 provides a quantitative analysis of the market size and development potential of each market segment in the next five years.

Chapter 13 is the main points and conclusions of the report.

Key Reasons to Buy this Report:

Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change

This enables you to anticipate market changes to remain ahead of your competitors

You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents

The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly

Provision of market value data for each segment and sub-segment

Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market

Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region

Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled

Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players

The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions

Includes in-depth analysis of the market from various perspectives through Porter's five forces analysis

Provides insight into the market through Value Chain

Market dynamics scenario, along with growth opportunities of the market in the years to come

6-month post-sales analyst support

Customization of the Report

In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.

Contents

1 RESEARCH METHODOLOGY AND STATISTICAL SCOPE

1.1 Market Definition and Statistical Scope of Granulomatosis With Polyangiitis Drug

1.2 Key Market Segments

1.2.1 Granulomatosis With Polyangiitis Drug Segment by Type

1.2.2 Granulomatosis With Polyangiitis Drug Segment by Application

1.3 Methodology & Sources of Information

1.3.1 Research Methodology

1.3.2 Research Process

1.3.3 Market Breakdown and Data Triangulation

1.3.4 Base Year

1.3.5 Report Assumptions & Caveats

2 GRANULOMATOSIS WITH POLYANGIITIS DRUG MARKET OVERVIEW

2.1 Global Market Overview

2.1.1 Global Granulomatosis With Polyangiitis Drug Market Size (M USD) Estimates and Forecasts (2020-2033)

2.1.2 Global Granulomatosis With Polyangiitis Drug Sales Estimates and Forecasts (2020-2033)

2.2 Market Segment Executive Summary

2.3 Global Market Size by Region

3 GRANULOMATOSIS WITH POLYANGIITIS DRUG MARKET COMPETITIVE LANDSCAPE

3.1 Company Assessment Quadrant

3.2 Global Granulomatosis With Polyangiitis Drug Product Life Cycle

3.3 Global Granulomatosis With Polyangiitis Drug Sales by Manufacturers (2020-2025)

3.4 Global Granulomatosis With Polyangiitis Drug Revenue Market Share by Manufacturers (2020-2025)

3.5 Granulomatosis With Polyangiitis Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.6 Global Granulomatosis With Polyangiitis Drug Average Price by Manufacturers (2020-2025)

3.7 Manufacturers? Manufacturing Sites, Areas Served, and Product Types

3.8 Granulomatosis With Polyangiitis Drug Market Competitive Situation and Trends

- 3.8.1 Granulomatosis With Polyangiitis Drug Market Concentration Rate
- 3.8.2 Global 5 and 10 Largest Granulomatosis With Polyangiitis Drug Players Market Share by Revenue
- 3.8.3 Mergers & Acquisitions, Expansion

4 GRANULOMATOSIS WITH POLYANGIITIS DRUG INDUSTRY CHAIN ANALYSIS

- 4.1 Granulomatosis With Polyangiitis Drug Industry Chain Analysis
- 4.2 Market Overview of Key Raw Materials
- 4.3 Midstream Market Analysis
- 4.4 Downstream Customer Analysis

5 THE DEVELOPMENT AND DYNAMICS OF GRANULOMATOSIS WITH POLYANGIITIS DRUG MARKET

- 5.1 Key Development Trends
- 5.2 Driving Factors
- 5.3 Market Challenges
- 5.4 Industry News
 - 5.4.1 New Product Developments
 - 5.4.2 Mergers & Acquisitions
 - 5.4.3 Expansions
 - 5.4.4 Collaboration/Supply Contracts
- 5.5 PEST Analysis
 - 5.5.1 Industry Policies Analysis
 - 5.5.2 Economic Environment Analysis
 - 5.5.3 Social Environment Analysis
 - 5.5.4 Technological Environment Analysis
- 5.6 Global Granulomatosis With Polyangiitis Drug Market Porter's Five Forces Analysis
 - 5.6.1 Global Trade Frictions
 - 5.6.2 U.S. Tariff Policy ? April 2025
 - 5.6.3 Global Trade Frictions and Their Impacts to Granulomatosis With Polyangiitis Drug Market
- 5.7 ESG Ratings of Leading Companies

6 GRANULOMATOSIS WITH POLYANGIITIS DRUG MARKET SEGMENTATION BY TYPE

- 6.1 Evaluation Matrix of Segment Market Development Potential (Type)

6.2 Global Granulomatosis With Polyangiitis Drug Sales Market Share by Type (2020-2025)

6.3 Global Granulomatosis With Polyangiitis Drug Market Size Market Share by Type (2020-2025)

6.4 Global Granulomatosis With Polyangiitis Drug Price by Type (2020-2025)

7 GRANULOMATOSIS WITH POLYANGIITIS DRUG MARKET SEGMENTATION BY APPLICATION

7.1 Evaluation Matrix of Segment Market Development Potential (Application)

7.2 Global Granulomatosis With Polyangiitis Drug Market Sales by Application (2020-2025)

7.3 Global Granulomatosis With Polyangiitis Drug Market Size (M USD) by Application (2020-2025)

7.4 Global Granulomatosis With Polyangiitis Drug Sales Growth Rate by Application (2020-2025)

8 GRANULOMATOSIS WITH POLYANGIITIS DRUG MARKET SALES BY REGION

8.1 Global Granulomatosis With Polyangiitis Drug Sales by Region

8.1.1 Global Granulomatosis With Polyangiitis Drug Sales by Region

8.1.2 Global Granulomatosis With Polyangiitis Drug Sales Market Share by Region

8.2 Global Granulomatosis With Polyangiitis Drug Market Size by Region

8.2.1 Global Granulomatosis With Polyangiitis Drug Market Size by Region

8.2.2 Global Granulomatosis With Polyangiitis Drug Market Size Market Share by Region

8.3 North America

8.3.1 North America Granulomatosis With Polyangiitis Drug Sales by Country

8.3.2 North America Granulomatosis With Polyangiitis Drug Market Size by Country

8.3.3 U.S. Market Overview

8.3.4 Canada Market Overview

8.3.5 Mexico Market Overview

8.4 Europe

8.4.1 Europe Granulomatosis With Polyangiitis Drug Sales by Country

8.4.2 Europe Granulomatosis With Polyangiitis Drug Market Size by Country

8.4.3 Germany Market Overview

8.4.4 France Market Overview

8.4.5 U.K. Market Overview

8.4.6 Italy Market Overview

8.4.7 Spain Market Overview

8.5 Asia Pacific

8.5.1 Asia Pacific Granulomatosis With Polyangiitis Drug Sales by Region

8.5.2 Asia Pacific Granulomatosis With Polyangiitis Drug Market Size by Region

8.5.3 China Market Overview

8.5.4 Japan Market Overview

8.5.5 South Korea Market Overview

8.5.6 India Market Overview

8.5.7 Southeast Asia Market Overview

8.6 South America

8.6.1 South America Granulomatosis With Polyangiitis Drug Sales by Country

8.6.2 South America Granulomatosis With Polyangiitis Drug Market Size by Country

8.6.3 Brazil Market Overview

8.6.4 Argentina Market Overview

8.6.5 Columbia Market Overview

8.7 Middle East and Africa

8.7.1 Middle East and Africa Granulomatosis With Polyangiitis Drug Sales by Region

8.7.2 Middle East and Africa Granulomatosis With Polyangiitis Drug Market Size by Region

8.7.3 Saudi Arabia Market Overview

8.7.4 UAE Market Overview

8.7.5 Egypt Market Overview

8.7.6 Nigeria Market Overview

8.7.7 South Africa Market Overview

9 GRANULOMATOSIS WITH POLYANGIITIS DRUG MARKET PRODUCTION BY REGION

9.1 Global Production of Granulomatosis With Polyangiitis Drug by Region(2020-2025)

9.2 Global Granulomatosis With Polyangiitis Drug Revenue Market Share by Region (2020-2025)

9.3 Global Granulomatosis With Polyangiitis Drug Production, Revenue, Price and Gross Margin (2020-2025)

9.4 North America Granulomatosis With Polyangiitis Drug Production

9.4.1 North America Granulomatosis With Polyangiitis Drug Production Growth Rate (2020-2025)

9.4.2 North America Granulomatosis With Polyangiitis Drug Production, Revenue, Price and Gross Margin (2020-2025)

9.5 Europe Granulomatosis With Polyangiitis Drug Production

9.5.1 Europe Granulomatosis With Polyangiitis Drug Production Growth Rate (2020-2025)

9.5.2 Europe Granulomatosis With Polyangiitis Drug Production, Revenue, Price and Gross Margin (2020-2025)

9.6 Japan Granulomatosis With Polyangiitis Drug Production (2020-2025)

9.6.1 Japan Granulomatosis With Polyangiitis Drug Production Growth Rate (2020-2025)

9.6.2 Japan Granulomatosis With Polyangiitis Drug Production, Revenue, Price and Gross Margin (2020-2025)

9.7 China Granulomatosis With Polyangiitis Drug Production (2020-2025)

9.7.1 China Granulomatosis With Polyangiitis Drug Production Growth Rate (2020-2025)

9.7.2 China Granulomatosis With Polyangiitis Drug Production, Revenue, Price and Gross Margin (2020-2025)

10 KEY COMPANIES PROFILE

10.1 Bionovis SA

10.1.1 Bionovis SA Basic Information

10.1.2 Bionovis SA Granulomatosis With Polyangiitis Drug Product Overview

10.1.3 Bionovis SA Granulomatosis With Polyangiitis Drug Product Market Performance

10.1.4 Bionovis SA Business Overview

10.1.5 Bionovis SA SWOT Analysis

10.1.6 Bionovis SA Recent Developments

10.2 Bristol-Myers Squibb Company

10.2.1 Bristol-Myers Squibb Company Basic Information

10.2.2 Bristol-Myers Squibb Company Granulomatosis With Polyangiitis Drug Product Overview

10.2.3 Bristol-Myers Squibb Company Granulomatosis With Polyangiitis Drug Product Market Performance

10.2.4 Bristol-Myers Squibb Company Business Overview

10.2.5 Bristol-Myers Squibb Company SWOT Analysis

10.2.6 Bristol-Myers Squibb Company Recent Developments

10.3 ChemoCentryx Inc

10.3.1 ChemoCentryx Inc Basic Information

10.3.2 ChemoCentryx Inc Granulomatosis With Polyangiitis Drug Product Overview

10.3.3 ChemoCentryx Inc Granulomatosis With Polyangiitis Drug Product Market Performance

- 10.3.4 ChemoCentryx Inc Business Overview
- 10.3.5 ChemoCentryx Inc SWOT Analysis
- 10.3.6 ChemoCentryx Inc Recent Developments
- 10.4 Coherus BioSciences Inc
 - 10.4.1 Coherus BioSciences Inc Basic Information
 - 10.4.2 Coherus BioSciences Inc Granulomatosis With Polyangiitis Drug Product Overview
 - 10.4.3 Coherus BioSciences Inc Granulomatosis With Polyangiitis Drug Product Market Performance
 - 10.4.4 Coherus BioSciences Inc Business Overview
 - 10.4.5 Coherus BioSciences Inc Recent Developments
- 10.5 Genor BioPharma Co Ltd
 - 10.5.1 Genor BioPharma Co Ltd Basic Information
 - 10.5.2 Genor BioPharma Co Ltd Granulomatosis With Polyangiitis Drug Product Overview
 - 10.5.3 Genor BioPharma Co Ltd Granulomatosis With Polyangiitis Drug Product Market Performance
 - 10.5.4 Genor BioPharma Co Ltd Business Overview
 - 10.5.5 Genor BioPharma Co Ltd Recent Developments
- 10.6 GlaxoSmithKline Plc
 - 10.6.1 GlaxoSmithKline Plc Basic Information
 - 10.6.2 GlaxoSmithKline Plc Granulomatosis With Polyangiitis Drug Product Overview
 - 10.6.3 GlaxoSmithKline Plc Granulomatosis With Polyangiitis Drug Product Market Performance
 - 10.6.4 GlaxoSmithKline Plc Business Overview
 - 10.6.5 GlaxoSmithKline Plc Recent Developments
- 10.7 Iltoo Pharma
 - 10.7.1 Iltoo Pharma Basic Information
 - 10.7.2 Iltoo Pharma Granulomatosis With Polyangiitis Drug Product Overview
 - 10.7.3 Iltoo Pharma Granulomatosis With Polyangiitis Drug Product Market Performance
 - 10.7.4 Iltoo Pharma Business Overview
 - 10.7.5 Iltoo Pharma Recent Developments
- 10.8 Panacea Biotec Ltd
 - 10.8.1 Panacea Biotec Ltd Basic Information
 - 10.8.2 Panacea Biotec Ltd Granulomatosis With Polyangiitis Drug Product Overview
 - 10.8.3 Panacea Biotec Ltd Granulomatosis With Polyangiitis Drug Product Market Performance
 - 10.8.4 Panacea Biotec Ltd Business Overview

- 10.8.5 Panacea Biotec Ltd Recent Developments
- 10.9 Sandoz International GmbH
 - 10.9.1 Sandoz International GmbH Basic Information
 - 10.9.2 Sandoz International GmbH Granulomatosis With Polyangiitis Drug Product Overview
 - 10.9.3 Sandoz International GmbH Granulomatosis With Polyangiitis Drug Product Market Performance
 - 10.9.4 Sandoz International GmbH Business Overview
 - 10.9.5 Sandoz International GmbH Recent Developments
- 10.10 The International Biotechnology Center (IBC) Generium
 - 10.10.1 The International Biotechnology Center (IBC) Generium Basic Information
 - 10.10.2 The International Biotechnology Center (IBC) Generium Granulomatosis With Polyangiitis Drug Product Overview
 - 10.10.3 The International Biotechnology Center (IBC) Generium Granulomatosis With Polyangiitis Drug Product Market Performance
 - 10.10.4 The International Biotechnology Center (IBC) Generium Business Overview
 - 10.10.5 The International Biotechnology Center (IBC) Generium Recent Developments

11 GRANULOMATOSIS WITH POLYANGIITIS DRUG MARKET FORECAST BY REGION

- 11.1 Global Granulomatosis With Polyangiitis Drug Market Size Forecast
- 11.2 Global Granulomatosis With Polyangiitis Drug Market Forecast by Region
 - 11.2.1 North America Market Size Forecast by Country
 - 11.2.2 Europe Granulomatosis With Polyangiitis Drug Market Size Forecast by Country
 - 11.2.3 Asia Pacific Granulomatosis With Polyangiitis Drug Market Size Forecast by Region
 - 11.2.4 South America Granulomatosis With Polyangiitis Drug Market Size Forecast by Country
 - 11.2.5 Middle East and Africa Forecasted Sales of Granulomatosis With Polyangiitis Drug by Country

12 FORECAST MARKET BY TYPE AND BY APPLICATION (2026-2033)

- 12.1 Global Granulomatosis With Polyangiitis Drug Market Forecast by Type (2026-2033)
 - 12.1.1 Global Forecasted Sales of Granulomatosis With Polyangiitis Drug by Type (2026-2033)

12.1.2 Global Granulomatosis With Polyangiitis Drug Market Size Forecast by Type (2026-2033)

12.1.3 Global Forecasted Price of Granulomatosis With Polyangiitis Drug by Type (2026-2033)

12.2 Global Granulomatosis With Polyangiitis Drug Market Forecast by Application (2026-2033)

12.2.1 Global Granulomatosis With Polyangiitis Drug Sales (K MT) Forecast by Application

12.2.2 Global Granulomatosis With Polyangiitis Drug Market Size (M USD) Forecast by Application (2026-2033)

13 CONCLUSION AND KEY FINDINGS

List Of Tables

LIST OF TABLES

Table 1. Introduction of the Type

Table 2. Introduction of the Application

Table 3. Market Size (M USD) Segment Executive Summary

Table 4. Granulomatosis With Polyangiitis Drug Market Size Comparison by Region (M USD)

Table 5. Global Granulomatosis With Polyangiitis Drug Sales (K MT) by Manufacturers (2020-2025)

Table 6. Global Granulomatosis With Polyangiitis Drug Sales Market Share by Manufacturers (2020-2025)

Table 7. Global Granulomatosis With Polyangiitis Drug Revenue (M USD) by Manufacturers (2020-2025)

Table 8. Global Granulomatosis With Polyangiitis Drug Revenue Share by Manufacturers (2020-2025)

Table 9. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Granulomatosis With Polyangiitis Drug as of 2024)

Table 10. Global Market Granulomatosis With Polyangiitis Drug Average Price (USD/KG) of Key Manufacturers (2020-2025)

Table 11. Manufacturers? Manufacturing Sites, Areas Served

Table 12. Manufacturers? Product Type

Table 13. Global Granulomatosis With Polyangiitis Drug Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 14. Mergers & Acquisitions, Expansion Plans

Table 15. Market Overview of Key Raw Materials

Table 16. Midstream Market Analysis

Table 17. Downstream Customer Analysis

Table 18. Key Development Trends

Table 19. Driving Factors

Table 20. Granulomatosis With Polyangiitis Drug Market Challenges

Table 21. Goldman Sachs' forecast real GDP growth rate for 2024-2026

Table 22. S&P Global ' Forecast Real GDP Growth Rate For 2024-2027

Table 23. World Bank ' Forecast Real GDP Growth Rate For 2024-2026

Table 24. The Tariff Rates Imposed by the United States on Major Commodity Trading Countries

Table 25. Global Granulomatosis With Polyangiitis Drug Sales by Type (K MT)

Table 26. Global Granulomatosis With Polyangiitis Drug Market Size by Type (M USD)

Table 27. Global Granulomatosis With Polyangiitis Drug Sales (K MT) by Type (2020-2025)

Table 28. Global Granulomatosis With Polyangiitis Drug Sales Market Share by Type (2020-2025)

Table 29. Global Granulomatosis With Polyangiitis Drug Market Size (M USD) by Type (2020-2025)

Table 30. Global Granulomatosis With Polyangiitis Drug Market Size Share by Type (2020-2025)

Table 31. Global Granulomatosis With Polyangiitis Drug Price (USD/KG) by Type (2020-2025)

Table 32. Global Granulomatosis With Polyangiitis Drug Sales (K MT) by Application

Table 33. Global Granulomatosis With Polyangiitis Drug Market Size by Application

Table 34. Global Granulomatosis With Polyangiitis Drug Sales by Application (2020-2025) & (K MT)

Table 35. Global Granulomatosis With Polyangiitis Drug Sales Market Share by Application (2020-2025)

Table 36. Global Granulomatosis With Polyangiitis Drug Market Size by Application (2020-2025) & (M USD)

Table 37. Global Granulomatosis With Polyangiitis Drug Market Share by Application (2020-2025)

Table 38. Global Granulomatosis With Polyangiitis Drug Sales Growth Rate by Application (2020-2025)

Table 39. Global Granulomatosis With Polyangiitis Drug Sales by Region (2020-2025) & (K MT)

Table 40. Global Granulomatosis With Polyangiitis Drug Sales Market Share by Region (2020-2025)

Table 41. Global Granulomatosis With Polyangiitis Drug Market Size by Region (2020-2025) & (M USD)

Table 42. Global Granulomatosis With Polyangiitis Drug Market Size Market Share by Region (2020-2025)

Table 43. North America Granulomatosis With Polyangiitis Drug Sales by Country (2020-2025) & (K MT)

Table 44. North America Granulomatosis With Polyangiitis Drug Market Size by Country (2020-2025) & (M USD)

Table 45. Europe Granulomatosis With Polyangiitis Drug Sales by Country (2020-2025) & (K MT)

Table 46. Europe Granulomatosis With Polyangiitis Drug Market Size by Country (2020-2025) & (M USD)

Table 47. Asia Pacific Granulomatosis With Polyangiitis Drug Sales by Region

(2020-2025) & (K MT)

Table 48. Asia Pacific Granulomatosis With Polyangiitis Drug Market Size by Region (2020-2025) & (M USD)

Table 49. South America Granulomatosis With Polyangiitis Drug Sales by Country (2020-2025) & (K MT)

Table 50. South America Granulomatosis With Polyangiitis Drug Market Size by Country (2020-2025) & (M USD)

Table 51. Middle East and Africa Granulomatosis With Polyangiitis Drug Sales by Region (2020-2025) & (K MT)

Table 52. Middle East and Africa Granulomatosis With Polyangiitis Drug Market Size by Region (2020-2025) & (M USD)

Table 53. Global Granulomatosis With Polyangiitis Drug Production (K MT) by Region(2020-2025)

Table 54. Global Granulomatosis With Polyangiitis Drug Revenue (US\$ Million) by Region (2020-2025)

Table 55. Global Granulomatosis With Polyangiitis Drug Revenue Market Share by Region (2020-2025)

Table 56. Global Granulomatosis With Polyangiitis Drug Production (K MT), Revenue (US\$ Million), Price (USD/KG) and Gross Margin (2020-2025)

Table 57. North America Granulomatosis With Polyangiitis Drug Production (K MT), Revenue (US\$ Million), Price (USD/KG) and Gross Margin (2020-2025)

Table 58. Europe Granulomatosis With Polyangiitis Drug Production (K MT), Revenue (US\$ Million), Price (USD/KG) and Gross Margin (2020-2025)

Table 59. Japan Granulomatosis With Polyangiitis Drug Production (K MT), Revenue (US\$ Million), Price (USD/KG) and Gross Margin (2020-2025)

Table 60. China Granulomatosis With Polyangiitis Drug Production (K MT), Revenue (US\$ Million), Price (USD/KG) and Gross Margin (2020-2025)

Table 61. Bionovis SA Basic Information

Table 62. Bionovis SA Granulomatosis With Polyangiitis Drug Product Overview

Table 63. Bionovis SA Granulomatosis With Polyangiitis Drug Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)

Table 64. Bionovis SA Business Overview

Table 65. Bionovis SA SWOT Analysis

Table 66. Bionovis SA Recent Developments

Table 67. Bristol-Myers Squibb Company Basic Information

Table 68. Bristol-Myers Squibb Company Granulomatosis With Polyangiitis Drug Product Overview

Table 69. Bristol-Myers Squibb Company Granulomatosis With Polyangiitis Drug Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)

Table 70. Bristol-Myers Squibb Company Business Overview
Table 71. Bristol-Myers Squibb Company SWOT Analysis
Table 72. Bristol-Myers Squibb Company Recent Developments
Table 73. ChemoCentryx Inc Basic Information
Table 74. ChemoCentryx Inc Granulomatosis With Polyangiitis Drug Product Overview
Table 75. ChemoCentryx Inc Granulomatosis With Polyangiitis Drug Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 76. ChemoCentryx Inc Business Overview
Table 77. ChemoCentryx Inc SWOT Analysis
Table 78. ChemoCentryx Inc Recent Developments
Table 79. Coherus BioSciences Inc Basic Information
Table 80. Coherus BioSciences Inc Granulomatosis With Polyangiitis Drug Product Overview
Table 81. Coherus BioSciences Inc Granulomatosis With Polyangiitis Drug Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 82. Coherus BioSciences Inc Business Overview
Table 83. Coherus BioSciences Inc Recent Developments
Table 84. Genor BioPharma Co Ltd Basic Information
Table 85. Genor BioPharma Co Ltd Granulomatosis With Polyangiitis Drug Product Overview
Table 86. Genor BioPharma Co Ltd Granulomatosis With Polyangiitis Drug Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 87. Genor BioPharma Co Ltd Business Overview
Table 88. Genor BioPharma Co Ltd Recent Developments
Table 89. GlaxoSmithKline Plc Basic Information
Table 90. GlaxoSmithKline Plc Granulomatosis With Polyangiitis Drug Product Overview
Table 91. GlaxoSmithKline Plc Granulomatosis With Polyangiitis Drug Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 92. GlaxoSmithKline Plc Business Overview
Table 93. GlaxoSmithKline Plc Recent Developments
Table 94. Iltoo Pharma Basic Information
Table 95. Iltoo Pharma Granulomatosis With Polyangiitis Drug Product Overview
Table 96. Iltoo Pharma Granulomatosis With Polyangiitis Drug Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 97. Iltoo Pharma Business Overview
Table 98. Iltoo Pharma Recent Developments
Table 99. Panacea Biotec Ltd Basic Information
Table 100. Panacea Biotec Ltd Granulomatosis With Polyangiitis Drug Product

Overview

Table 101. Panacea Biotech Ltd Granulomatosis With Polyangiitis Drug Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)

Table 102. Panacea Biotech Ltd Business Overview

Table 103. Panacea Biotech Ltd Recent Developments

Table 104. Sandoz International GmbH Basic Information

Table 105. Sandoz International GmbH Granulomatosis With Polyangiitis Drug Product Overview

Table 106. Sandoz International GmbH Granulomatosis With Polyangiitis Drug Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)

Table 107. Sandoz International GmbH Business Overview

Table 108. Sandoz International GmbH Recent Developments

Table 109. The International Biotechnology Center (IBC) Generium Basic Information

Table 110. The International Biotechnology Center (IBC) Generium Granulomatosis With Polyangiitis Drug Product Overview

Table 111. The International Biotechnology Center (IBC) Generium Granulomatosis With Polyangiitis Drug Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)

Table 112. The International Biotechnology Center (IBC) Generium Business Overview

Table 113. The International Biotechnology Center (IBC) Generium Recent Developments

Table 114. Global Granulomatosis With Polyangiitis Drug Sales Forecast by Region (2026-2033) & (K MT)

Table 115. Global Granulomatosis With Polyangiitis Drug Market Size Forecast by Region (2026-2033) & (M USD)

Table 116. North America Granulomatosis With Polyangiitis Drug Sales Forecast by Country (2026-2033) & (K MT)

Table 117. North America Granulomatosis With Polyangiitis Drug Market Size Forecast by Country (2026-2033) & (M USD)

Table 118. Europe Granulomatosis With Polyangiitis Drug Sales Forecast by Country (2026-2033) & (K MT)

Table 119. Europe Granulomatosis With Polyangiitis Drug Market Size Forecast by Country (2026-2033) & (M USD)

Table 120. Asia Pacific Granulomatosis With Polyangiitis Drug Sales Forecast by Region (2026-2033) & (K MT)

Table 121. Asia Pacific Granulomatosis With Polyangiitis Drug Market Size Forecast by Region (2026-2033) & (M USD)

Table 122. South America Granulomatosis With Polyangiitis Drug Sales Forecast by Country (2026-2033) & (K MT)

Table 123. South America Granulomatosis With Polyangiitis Drug Market Size Forecast by Country (2026-2033) & (M USD)

Table 124. Middle East and Africa Granulomatosis With Polyangiitis Drug Sales Forecast by Country (2026-2033) & (Units)

Table 125. Middle East and Africa Granulomatosis With Polyangiitis Drug Market Size Forecast by Country (2026-2033) & (M USD)

Table 126. Global Granulomatosis With Polyangiitis Drug Sales Forecast by Type (2026-2033) & (K MT)

Table 127. Global Granulomatosis With Polyangiitis Drug Market Size Forecast by Type (2026-2033) & (M USD)

Table 128. Global Granulomatosis With Polyangiitis Drug Price Forecast by Type (2026-2033) & (USD/KG)

Table 129. Global Granulomatosis With Polyangiitis Drug Sales (K MT) Forecast by Application (2026-2033)

Table 130. Global Granulomatosis With Polyangiitis Drug Market Size Forecast by Application (2026-2033) & (M USD)

List Of Figures

LIST OF FIGURES

- Figure 1. Product Picture of Granulomatosis With Polyangiitis Drug
- Figure 2. Data Triangulation
- Figure 3. Key Caveats
- Figure 4. Global Granulomatosis With Polyangiitis Drug Market Size (M USD), 2024-2033
- Figure 5. Global Granulomatosis With Polyangiitis Drug Market Size (M USD) (2020-2033)
- Figure 6. Global Granulomatosis With Polyangiitis Drug Sales (K MT) & (2020-2033)
- Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)
- Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)
- Figure 9. Evaluation Matrix of Regional Market Development Potential
- Figure 10. Granulomatosis With Polyangiitis Drug Market Size by Country (M USD)
- Figure 11. Company Assessment Quadrant
- Figure 12. Global Granulomatosis With Polyangiitis Drug Product Life Cycle
- Figure 13. Granulomatosis With Polyangiitis Drug Sales Share by Manufacturers in 2024
- Figure 14. Global Granulomatosis With Polyangiitis Drug Revenue Share by Manufacturers in 2024
- Figure 15. Granulomatosis With Polyangiitis Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2024
- Figure 16. Global Market Granulomatosis With Polyangiitis Drug Average Price (USD/KG) of Key Manufacturers in 2024
- Figure 17. The Global 5 and 10 Largest Players: Market Share by Granulomatosis With Polyangiitis Drug Revenue in 2024
- Figure 18. Industry Chain Map of Granulomatosis With Polyangiitis Drug
- Figure 19. Global Granulomatosis With Polyangiitis Drug Market PEST Analysis
- Figure 20. Global Granulomatosis With Polyangiitis Drug Market Porter's Five Forces Analysis
- Figure 21. Global Merchandise Trade as a Percentage Of GDP
- Figure 22. US - Imports of Goods by Country
- Figure 23. China Exports by Country
- Figure 24. ESG Rating Distribution of The Leading Company Compared With Its Peers
- Figure 25. Evaluation Matrix of Segment Market Development Potential (Type)
- Figure 26. Global Granulomatosis With Polyangiitis Drug Market Share by Type
- Figure 27. Sales Market Share of Granulomatosis With Polyangiitis Drug by Type

(2020-2025)

Figure 28. Sales Market Share of Granulomatosis With Polyangiitis Drug by Type in 2024

Figure 29. Market Size Share of Granulomatosis With Polyangiitis Drug by Type (2020-2025)

Figure 30. Market Size Share of Granulomatosis With Polyangiitis Drug by Type in 2024

Figure 31. Evaluation Matrix of Segment Market Development Potential (Application)

Figure 32. Global Granulomatosis With Polyangiitis Drug Market Share by Application

Figure 33. Global Granulomatosis With Polyangiitis Drug Sales Market Share by Application (2020-2025)

Figure 34. Global Granulomatosis With Polyangiitis Drug Sales Market Share by Application in 2024

Figure 35. Global Granulomatosis With Polyangiitis Drug Market Share by Application (2020-2025)

Figure 36. Global Granulomatosis With Polyangiitis Drug Market Share by Application in 2024

Figure 37. Global Granulomatosis With Polyangiitis Drug Sales Growth Rate by Application (2020-2025)

Figure 38. Global Granulomatosis With Polyangiitis Drug Sales Market Share by Region (2020-2025)

Figure 39. Global Granulomatosis With Polyangiitis Drug Market Size Market Share by Region (2020-2025)

Figure 40. North America Granulomatosis With Polyangiitis Drug Sales and Growth Rate (2020-2025) & (K MT)

Figure 41. North America Granulomatosis With Polyangiitis Drug Sales and Growth Rate (2020-2025) & (K MT)

Figure 42. North America Granulomatosis With Polyangiitis Drug Sales Market Share by Country in 2024

Figure 43. North America Granulomatosis With Polyangiitis Drug Market Size and Growth Rate (2020-2025) & (M USD)

Figure 44. North America Granulomatosis With Polyangiitis Drug Market Size Market Share by Country in 2024

Figure 45. U.S. Granulomatosis With Polyangiitis Drug Sales and Growth Rate (2020-2025) & (K MT)

Figure 46. U.S. Granulomatosis With Polyangiitis Drug Market Size and Growth Rate (2020-2025) & (M USD)

Figure 47. Canada Granulomatosis With Polyangiitis Drug Sales (K MT) and Growth Rate (2020-2025)

Figure 48. Canada Granulomatosis With Polyangiitis Drug Market Size (M USD) and

Growth Rate (2020-2025)

Figure 49. Mexico Granulomatosis With Polyangiitis Drug Sales (Units) and Growth Rate (2020-2025)

Figure 50. Mexico Granulomatosis With Polyangiitis Drug Market Size (Units) and Growth Rate (2020-2025)

Figure 51. Europe Granulomatosis With Polyangiitis Drug Sales and Growth Rate (2020-2025) & (K MT)

Figure 52. Europe Granulomatosis With Polyangiitis Drug Sales Market Share by Country in 2024

Figure 53. Europe Granulomatosis With Polyangiitis Drug Market Size and Growth Rate (2020-2025) & (M USD)

Figure 54. Europe Granulomatosis With Polyangiitis Drug Market Size Market Share by Country in 2024

Figure 55. Germany Granulomatosis With Polyangiitis Drug Sales and Growth Rate (2020-2025) & (K MT)

Figure 56. Germany Granulomatosis With Polyangiitis Drug Market Size and Growth Rate (2020-2025) & (M USD)

Figure 57. France Granulomatosis With Polyangiitis Drug Sales and Growth Rate (2020-2025) & (K MT)

Figure 58. France Granulomatosis With Polyangiitis Drug Market Size and Growth Rate (2020-2025) & (M USD)

Figure 59. U.K. Granulomatosis With Polyangiitis Drug Sales and Growth Rate (2020-2025) & (K MT)

Figure 60. U.K. Granulomatosis With Polyangiitis Drug Market Size and Growth Rate (2020-2025) & (M USD)

Figure 61. Italy Granulomatosis With Polyangiitis Drug Sales and Growth Rate (2020-2025) & (K MT)

Figure 62. Italy Granulomatosis With Polyangiitis Drug Market Size and Growth Rate (2020-2025) & (M USD)

Figure 63. Spain Granulomatosis With Polyangiitis Drug Sales and Growth Rate (2020-2025) & (K MT)

Figure 64. Spain Granulomatosis With Polyangiitis Drug Market Size and Growth Rate (2020-2025) & (M USD)

Figure 65. Asia Pacific Granulomatosis With Polyangiitis Drug Sales and Growth Rate (K MT)

Figure 66. Asia Pacific Granulomatosis With Polyangiitis Drug Sales Market Share by Region in 2024

Figure 67. Asia Pacific Granulomatosis With Polyangiitis Drug Market Size Market Share by Region in 2024

Figure 68. China Granulomatosis With Polyangiitis Drug Sales and Growth Rate (2020-2025) & (K MT)

Figure 69. China Granulomatosis With Polyangiitis Drug Market Size and Growth Rate (2020-2025) & (M USD)

Figure 70. Japan Granulomatosis With Polyangiitis Drug Sales and Growth Rate (2020-2025) & (K MT)

Figure 71. Japan Granulomatosis With Polyangiitis Drug Market Size and Growth Rate (2020-2025) & (M USD)

Figure 72. South Korea Granulomatosis With Polyangiitis Drug Sales and Growth Rate (2020-2025) & (K MT)

Figure 73. South Korea Granulomatosis With Polyangiitis Drug Market Size and Growth Rate (2020-2025) & (M USD)

Figure 74. India Granulomatosis With Polyangiitis Drug Sales and Growth Rate (2020-2025) & (K MT)

Figure 75. India Granulomatosis With Polyangiitis Drug Market Size and Growth Rate (2020-2025) & (M USD)

Figure 76. Southeast Asia Granulomatosis With Polyangiitis Drug Sales and Growth Rate (2020-2025) & (K MT)

Figure 77. Southeast Asia Granulomatosis With Polyangiitis Drug Market Size and Growth Rate (2020-2025) & (M USD)

Figure 78. South America Granulomatosis With Polyangiitis Drug Sales and Growth Rate (K MT)

Figure 79. South America Granulomatosis With Polyangiitis Drug Sales Market Share by Country in 2024

Figure 80. South America Granulomatosis With Polyangiitis Drug Market Size and Growth Rate (M USD)

Figure 81. South America Granulomatosis With Polyangiitis Drug Market Size Market Share by Country in 2024

Figure 82. Brazil Granulomatosis With Polyangiitis Drug Sales and Growth Rate (2020-2025) & (K MT)

Figure 83. Brazil Granulomatosis With Polyangiitis Drug Market Size and Growth Rate (2020-2025) & (M USD)

Figure 84. Argentina Granulomatosis With Polyangiitis Drug Sales and Growth Rate (2020-2025) & (K MT)

Figure 85. Argentina Granulomatosis With Polyangiitis Drug Market Size and Growth Rate (2020-2025) & (M USD)

Figure 86. Columbia Granulomatosis With Polyangiitis Drug Sales and Growth Rate (2020-2025) & (K MT)

Figure 87. Columbia Granulomatosis With Polyangiitis Drug Market Size and Growth

Rate (2020-2025) & (M USD)

Figure 88. Middle East and Africa Granulomatosis With Polyangiitis Drug Sales and Growth Rate (K MT)

Figure 89. Middle East and Africa Granulomatosis With Polyangiitis Drug Sales Market Share by Region in 2024

Figure 90. Middle East and Africa Granulomatosis With Polyangiitis Drug Market Size and Growth Rate (M USD)

Figure 91. Middle East and Africa Granulomatosis With Polyangiitis Drug Market Size Market Share by Region in 2024

Figure 92. Saudi Arabia Granulomatosis With Polyangiitis Drug Sales and Growth Rate (2020-2025) & (K MT)

Figure 93. Saudi Arabia Granulomatosis With Polyangiitis Drug Market Size and Growth Rate (2020-2025) & (M USD)

Figure 94. UAE Granulomatosis With Polyangiitis Drug Sales and Growth Rate (2020-2025) & (K MT)

Figure 95. UAE Granulomatosis With Polyangiitis Drug Market Size and Growth Rate (2020-2025) & (M USD)

Figure 96. Egypt Granulomatosis With Polyangiitis Drug Sales and Growth Rate (2020-2025) & (K MT)

Figure 97. Egypt Granulomatosis With Polyangiitis Drug Market Size and Growth Rate (2020-2025) & (M USD)

Figure 98. Nigeria Granulomatosis With Polyangiitis Drug Sales and Growth Rate (2020-2025) & (K MT)

Figure 99. Nigeria Granulomatosis With Polyangiitis Drug Market Size and Growth Rate (2020-2025) & (M USD)

Figure 100. South Africa Granulomatosis With Polyangiitis Drug Sales and Growth Rate (2020-2025) & (K MT)

Figure 101. South Africa Granulomatosis With Polyangiitis Drug Market Size and Growth Rate (2020-2025) & (M USD)

Figure 102. Global Granulomatosis With Polyangiitis Drug Production Market Share by Region (2020-2025)

Figure 103. North America Granulomatosis With Polyangiitis Drug Production (K MT) Growth Rate (2020-2025)

Figure 104. Europe Granulomatosis With Polyangiitis Drug Production (K MT) Growth Rate (2020-2025)

Figure 105. Japan Granulomatosis With Polyangiitis Drug Production (K MT) Growth Rate (2020-2025)

Figure 106. China Granulomatosis With Polyangiitis Drug Production (K MT) Growth Rate (2020-2025)

Figure 107. Global Granulomatosis With Polyangiitis Drug Sales Forecast by Volume (2020-2033) & (K MT)

Figure 108. Global Granulomatosis With Polyangiitis Drug Market Size Forecast by Value (2020-2033) & (M USD)

Figure 109. Global Granulomatosis With Polyangiitis Drug Sales Market Share Forecast by Type (2026-2033)

Figure 110. Global Granulomatosis With Polyangiitis Drug Market Share Forecast by Type (2026-2033)

Figure 111. Global Granulomatosis With Polyangiitis Drug Sales Forecast by Application (2026-2033)

Figure 112. Global Granulomatosis With Polyangiitis Drug Market Share Forecast by Application (2026-2033)

I would like to order

Product name: Global Granulomatosis With Polyangiitis Drug Market Research Report 2025(Status and Outlook)

Product link: <https://marketpublishers.com/r/GE0030AA4F08EN.html>

Price: US\$ 3,200.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GE0030AA4F08EN.html>